Cellzome, GSK Sign $45M Screening Pact

The companies will use Cellzome's Episphere chemical proteomics technology to identify candidates for anti-inflammatory drugs. If certain milestones are met, Cellzome could potentially receive €475 million.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.